Related Experiment Video

Updated: May 3, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

371

Gentian violet induces wtp53 transactivation in cancer cells

Alessia Garufi1, Valerio D'Orazi2, Jack L Arbiser3

  • 1Department of Experimental Oncology, Regina Elena National Cancer Institute, 00159 Rome, Italy.

International Journal of Oncology
|February 19, 2014
PubMed

Insights

Gentian violet (GV) reactivates the tumor suppressor p53, enhancing cancer cell death. This FDA-approved dye shows potential for cancer therapy by activating p53 and overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Overexpression of NADPH oxidases (Nox genes) is linked to tumor progression.
  • Nox1 overexpression inhibits the oncosuppressor p53, impairing cancer cell drug response.
  • p53 is a critical transcription factor for tumor growth inhibition and apoptosis.

Purpose of the Study:

  • To investigate the effect of gentian violet (GV) on wild-type p53 activity in cancer cells.
  • To determine if GV can overcome Nox1-mediated inhibition of p53.
  • To explore the therapeutic potential of GV in cancer management via p53 activation.

Main Methods:

  • Assessing GV's impact on p53 transcriptional activity in cancer cells.
  • Evaluating direct p53/DNA binding and transcriptional activity induction by GV.
  • Measuring GV-induced cancer cell death and PARP cleavage in p53-dependent and independent settings.

Main Results:

  • GV overcomes Nox1's inhibitory effect on p53 transcriptional activity.
  • GV directly induces p53/DNA binding and transcriptional activity.
  • GV induces cancer cell death and PARP cleavage, partly dependent on p53 activation.

Conclusions:

  • Gentian violet demonstrates anticancer activity by directly activating p53.
  • GV's ability to restore p53 function suggests therapeutic potential in cancer treatment.
  • The US FDA-approved status of GV facilitates its consideration for clinical application in oncology.

More Related Videos

The Lambda Select cII Mutation Detection System07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

7.5K
Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

8.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
31.2K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K